FDA Brief

Warning letters Drugs

FDA warning letter to

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

High riskIssued Jul 11, 2024Posted Jul 16, 2024Center for Drug Evaluation and Research (CDER)

FDA found data integrity failures and inadequate sterile manufacturing controls at Jiangsu Hengrui Pharmaceuticals' drug facility.

What happened

FDA inspected the facility from January 8 to 16, 2024. It found serious quality assurance problems, including discarded original current good manufacturing practice (CGMP) records and uncontrolled blank production records, and inadequate separation between sterile processing areas with inadequate smoke studies. FDA said the company's March 7, 2024 response was inadequate.

What FDA found

  1. The quality control unit did not adequately oversee manufacturing quality and data reliability.

    21 CFR 211.22
  2. Original CGMP records were found discarded in a bag under a vehicle and in a nearby trash can.

    21 CFR 211.22
  3. The production manager accessed and printed uncontrolled blank production, validation, and cleaning records without quality assurance issuance.

    21 CFR 211.22
  4. There was inadequate physical separation between Grade A and Grade B cleanroom areas for sterile drug manufacturing.

    21 CFR 211.42(c)(10)
  5. The facility lacked smoke studies to show airflow between the Grade A and Grade B transition areas outside the filling machine.

    21 CFR 211.42(c)(10)
  6. The transfer cart for drug vials was open on both sides, showed air turbulence, and did not monitor non-viable particles in the cart.

    21 CFR 211.42(c)(10)

What FDA wants

FDA asks the company to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. If corrective actions cannot be completed in that time, the company must state why and give a completion schedule.

Who should pay attention

  • companies using Jiangsu Hengrui as a drug manufacturer
  • buyers of sterile drug products from China
  • quality teams managing contract manufacturers or suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk